dcsimg
Home > Market Activity > Get Quotes > News > News Article

KP Tissue Inc.

Exchange: TSX Exchange | Apr 29, 2017, 1:30 AM EDT

KPT
$ 15.82 real time data Change Down
Change:
-0.18 (-1.13%)
Volume:
5,628
Real-time price
Day Low 15.82
Day High 16.00


 Back
,
CORRECTION: KP Tissue Releases Fourth Quarter and Full Year 2016 Financial Results

Record Results for 2016

MISSISSAUGA, ONTARIO--(Marketwired - March 9, 2017) - This document corrects and replaces the press release that was sent today at 7:00 am ET. Changes were made to the Segmented Adjusted EBITDA table for the fourth quarter 2016 results. These changes have no impact on overall results for the fourth quarter or full year.

KP Tissue Inc. (KPT) (TSX:KPT) reports the Q4 and full year 2016 financial and operational results of KPT and Kruger Products L.P. (KPLP). Kruger Products is Canada's leading manufacturer of quality tissue products for the Consumer market (Cashmere®, Purex®, SpongeTowels®, Scotties®, and White Swan®) and the Away-From-Home market, and continues to grow in the U.S. Consumer tissue business with the White Cloud® brand and premium private label products. KPT currently holds a 16.1% interest in KPLP.

KPLP Q4 2016 Business and Financial Highlights

  • Revenue increased by 13.0% to $339.6 million in Q4 2016 compared to Q4 2015
  • Adjusted EBITDA was $42.9 million in Q4 2016 compared to $30.3 million in Q4 2015, up 41.6%
  • Kruger Products continues to be the market share leader in Canada
  • Declared a quarterly dividend of $0.18 per share to be paid on April 17, 2017

KPLP Full Year 2016 Business and Financial Highlights

  • Revenue increased by 7.8% to $1,227.9 million in 2016 compared to $1,138.9 million in 2015
  • Adjusted EBITDA was $152.5 million in 2016, up from $126.4 million in 2015, a 20.6% increase

"We are extremely pleased with our results for Fiscal 2016. The record Revenue and Adjusted EBITDA performance was primarily due to higher sales volume, improved pricing and strong contribution from TAD products" said Mario Gosselin, CEO of KP Tissue and KPLP.

"We continue to be #1 in overall tissue market share in Canada, with share gains in our market leading position in the bathroom tissue category, while remaining the uncontested market leader in the facial tissue category and holding a strong #2 position in the paper towels category. In the U.S., we continue to leverage our TAD product manufacturing capacity to take advantage of growth opportunities in the U.S. premium private label market.

"In the past two years, our capital program has increased significantly, focused on projects related to capacity growth and cost reduction with quick paybacks, highlighted by our $55 million paper machine investment in Crabtree to reduce our overall paper costs. We are starting to see the benefits of these investments in our results, and expect a positive impact from capital projects on our costs going forward," concluded Mr. Gosselin.

Q1 2017 Outlook

For the first quarter of 2017, Adjusted EBITDA is expected to increase over Q1 2016, while being seasonally lower than the fourth quarter of 2016 due primarily to twelve fewer sales days and higher advertising expenses.

KPLP Q4 2016 Financial Results

Revenue in Q4 2016 was $339.6 million, compared to $300.6 million in Q4 2015, an increase of $39.0 million or 13.0%. The increase in revenue was primarily due to higher sales volumes and a selling price increase in Canada. 

Cost of sales in Q4 2016 increased to $284.2 million, compared to $259.9 million in Q4 2015, primarily due to higher sales volumes, somewhat offset by cost reduction initiatives and the impact of capital projects. As a percentage of revenue, cost of sales were 83.7% in Q4 2016 compared to 86.5% in Q4 2015.

Selling, general and administrative (SG&A) expenses in Q4 2016 were $26.4 million, compared to $23.5 million in Q4 2015. The increase was primarily due to higher selling expenses related to higher sales volumes and higher advertising expenses. As a percentage of revenue, SG&A expenses were 7.8% in Q4 2016, consistent with Q4 2015.

Adjusted EBITDA in Q4 2016 was $42.9 million, compared to $30.3 million in Q4 2015, primarily due to higher sales volume, improved pricing and mix of products sold, and the impact of cost reduction initiatives and capital projects, partially offset by higher SG&A costs. Adjusted EBITDA attributable to the sale of TAD products was $13.8 million in Q4 2016 compared to $13.2 million in Q4 2015.

Net loss in Q4 2016 was $4.5 million, compared to $0.5 million in Q4 2015, primarily due to a change in the amortized cost of the Partnership units liability of $23.2 million, and higher depreciation and interest expense of $1.2 million and $0.7 million, respectively. These increases were partially offset by higher Adjusted EBITDA of $12.6 million, a decrease in tax expense of $4.2 million, and a gain on sale of non-financial assets of $2.5 million. 

Total liquidity, representing cash and cash equivalents and availability under the credit line within covenant limitations, was $103.5 million as of December 31, 2016, compared to $90.6 million as of September 25, 2016.

KPLP 2016 Financial Results

Revenue was $1,227.9 million in Fiscal 2016, compared to $1,138.9 million in Fiscal 2015, an increase of $89.0 million or 7.8%. The increase in revenue was primarily due to additional sales volume across all regions as well as a selling price increase in Canada, and the favourable impact of foreign exchange on U.S. dollar sales. 

Adjusted EBITDA was $152.5 million in Fiscal 2016, compared to $126.4 million in Fiscal 2015. The increase was primarily due to higher sales volume, improved pricing and mix of products sold, and the impact of cost reduction initiatives and capital projects. These were partially offset by higher SG&A costs and the net negative impact of foreign exchange. Adjusted EBITDA attributable to the sale of TAD products was $49.0 million in Fiscal 2016 compared to $45.3 million in Fiscal 2015.

Net income was $35.5 million in Fiscal 2016, compared to $1.5 million in Fiscal 2015. The increase in net income was primarily due to higher Adjusted EBITDA of $26.1 million, a decrease in interest expense of $14.2 million, a change in the foreign exchange gain/loss of $7.2 million, a decrease in tax expense of $3.8 million, and no pension revaluation related to past service costs compared to $3.4 million in Fiscal 2015. These decreases were partially offset by a change in the amortized cost of the Partnership units liability of $19.4 million, and higher depreciation expense of $5.9 million.

KPT Q4 2016 Financial Results

KPT incurred a net loss of $0.4 million in Q4 2016. Included in the net loss was $0.7 million representing KPT's share of KPLP's loss. The loss was increased by the net of depreciation expense of $1.5 million related to adjustments to carrying amounts on acquisition, partially offset by an income tax recovery of $1.8 million.

KPT 2016 Financial Results

KPT incurred a net loss of $1.7 million in 2016. Included in the net loss was $5.8 million representing KPT's share of KPLP's income. The income was reduced by depreciation expense of $5.9 million related to adjustments to carrying amounts on acquisition and income tax expense of $1.8 million

Dividends on Common Shares

The Board of Directors of KPT declared a quarterly dividend of $0.18 per share to be paid on April 17, 2017 to shareholders of record at the close of business on March 31, 2017.

Additional Information

For additional information please refer to Management's Discussion and Analysis (MD&A) of KPT and KPLP for the fourth quarter and year ended December 31, 2016 available on SEDAR at www.sedar.com or our website at www.kptissueinc.com.

Fourth Quarter Results Conference Call Information

KPT will hold its fourth quarter conference call on Thursday, March 9, 2017 at 8:30 a.m. Eastern Time.

Via telephone: 1-877-223-4471 or 647-788-4922

Via the internet at: www.kptissueinc.com

Presentation material referenced during the conference call will be available at www.kptissueinc.com.

A rebroadcast of the conference call will be available until midnight, April 8, 2017 by dialing 800-585-8367 or 416-621-4642 and entering passcode 59685751.

The replay of the webcast will remain available on the website until midnight, April 8, 2017.

About KP Tissue Inc. (KPT)

KPT was created to acquire, and its business is limited to holding, a limited partnership interest in KPLP, which is accounted for as an investment on the equity basis. KPT currently holds a 16.1% interest in KPLP. For more information visit www.kptissueinc.com.

About Kruger Products L.P. (KPLP)

KPLP is Canada's leading manufacturer of quality tissue products for household, industrial and commercial use. KPLP serves the Canadian consumer market with such well-known brands as Cashmere®, Purex®, SpongeTowels®, Scotties® and White Swan®. In the U.S., KPLP manufactures the White Cloud® brand, as well as many private label products. The Away-From-Home division manufactures and distributes high-quality, cost-effective product solutions to a wide range of commercial and public entities. KPLP has approximately 2,500 employees and operates eight production facilities in North America, including five FSC® CoC-certified plants (FSC® C104904), four of which are located in Canada and one in the U.S. For more information visit www.krugerproducts.ca.

Non-IFRS Measures

This press release uses certain non-IFRS financial measures which KPLP believes provide useful information to management of KPLP and the readers of the financial information in measuring the financial performance and financial condition of KPLP. These measures do not have a standardized meaning prescribed by IFRS and therefore may not be comparable to similarly titled measures presented by other companies. An example of such a measure is Adjusted EBITDA. Beginning with Q4 2015 in accordance with Canadian Securities Administrators Staff Notice 52-306 (Revised), we reference Adjusted EBITDA as a non-IFRS financial measure. This term replaces the previously referenced non-IFRS financial measure EBITDA. Our definition of Adjusted EBITDA is unchanged from our former definition of EBITDA. Accordingly, this change in terminology has no impact on our reported financial results for prior periods. Adjusted EBITDA is not a measurement of operating performance computed in accordance with IFRS and should not be considered as a substitute for operating income, net income or cash flows from operating activities computed in accordance with IFRS. "Adjusted EBITDA" is calculated by KPLP as net income (loss) before (i) interest expense, (ii) income taxes, (iii) depreciation, (iv) amortization, (v) impairment (gain on sale) of non-financial assets, (vi) loss (gain) on disposal of property, plant and equipment, (vii) foreign exchange loss (gain), (viii) costs related to restructuring activities, (ix) changes in the amortized cost of the Partnership units liability, and (x) one-time costs due to pension revaluations related to past service. A reconciliation of Adjusted EBITDA to the relevant reported results can be found in the MD&A of KPT and KPLP for the fourth quarter ended December 31, 2016 available on SEDAR at www.sedar.com.

Forward-Looking Statements

Certain statements in this press release about KPT's and KPLP's current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements or any other future events or developments constitute forward-looking statements. The words "may", "will", "would", "should", "could", "expects", "plans", "intends", "trends", "indications", "anticipates", "believes", "estimates", "predicts", "likely" or "potential" or the negative or other variations of these words or other comparable words or phrases, are intended to identify forward-looking statements. The forward-looking information is based on certain key expectations and assumptions made by KPT, including expectations and assumptions concerning the impact of the TAD Project on Adjusted EBITDA, the expectation of continued growth in sales of TAD products in the U.S., and stable interest rates. Although KPT believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information since no assurance can be given that such expectations and assumptions will prove to be correct.

The outlook provided in respect of Adjusted EBITDA for Q1 2017 is forward-looking information and is subject to the risk and uncertainties referred to below. The purpose of the outlook is to provide the reader with an indication of management's expectations, at the date of this press release, regarding KPLP's future financial performance. Readers are cautioned that this information may not be appropriate for other purposes. 

Many factors could cause KPLP's actual results, level of activity, performance or achievements or future events or developments (which could in turn affect the economic benefits derived from the Corporation's economic interest in KPLP) to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, the following factors, which are discussed in greater detail in the "Risk Factors - Risks Related to KPLP's Business" section of the KPT Annual Information Form dated March 9, 2017 available on SEDAR at www.sedar.com: Kruger Inc.'s influence over KPLP; KPLP's reliance on Kruger Inc.; consequences of an event of insolvency relating to Kruger Inc.; risks associated with the TAD Project; operational risks; Gatineau Plant land lease; significant increases in input costs; reduction in supply of fibre; increased pricing pressure and intense competition; KPLP's inability to innovate effectively; adverse economic conditions; dependence on key retail trade customers; damage to the reputation of KPLP or KPLP's brands; KPLP's sales being less than anticipated; KPLP's failure to implement its business and operating strategies; KPLP's obligation to make regular capital expenditures; KPLP's entering into unsuccessful acquisitions; KPLP's dependence on key personnel; KPLP's inability to retain its existing customers or obtain new customers; KPLP's loss of key suppliers; KPLP's failure to adequately protect its intellectual property rights; KPLP's reliance on third party intellectual property licenses; adverse litigation and other claims affecting KPLP; material expenditures due to comprehensive environmental regulation affecting KPLP's cash flow; KPLP's pension obligations are significant and can be materially higher than predicted if KPLP Management's underlying assumptions are incorrect; labour disputes adversely affecting KPLP's cost structure and KPLP's ability to run its plants; exchange rate and U.S. competitors; KPLP's inability to service all of its indebtedness; exposure to potential consumer product liability, restrictive covenants; interest rate and refinancing risk; information technology; cyber-security; insurance; internal controls and trade related risk.

Readers should not place undue reliance on forward-looking statements made herein. The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. The forward-looking information contained herein is made as of the date of press release and KPT undertakes no obligation to publicly update such forward-looking information to reflect new information, subsequent or otherwise, unless required by applicable securities laws.

Kruger Products L.P.  
Consolidated Statement of Financial Position  
(thousands of Canadian dollars)  
         
  December 31, 2016   December 31, 2015  
  $   $  
Assets        
Current assets        
  Cash and cash equivalents 36,511   25,455  
  Trade and other receivables 123,095   108,720  
  Receivables from related parties 185   185  
  Current portion of advances to partners 5,465   2,630  
  Inventories 179,543   184,985  
  Income tax recoverable 423   772  
  Prepaid expenses 7,286   8,429  
  352,508   331,176  
Non-current assets        
  Advances to partners -   4,234  
  Property, plant & equipment 762,270   737,708  
  Other long-term assets 6,075   8,107  
  Goodwill 160,939   160,939  
  Intangible assets 15,270   15,853  
  Deferred income taxes 39,913   39,411  
Total assets 1,336,975   1,297,428  
         
Liabilities        
Current liabilities        
  Bank indebtedness 9,007   -  
  Trade and other payables 201,477   180,329  
  Payables to related parties 3,606   3,775  
  Income tax payable 1,779   -  
  Distributions payable 10,148   9,871  
  Current portion of provisions 1,885   3,096  
  Current portion of long-term debt 8,859   10,183  
  236,761   207,254  
Non-current liabilities        
  Long-term debt 415,379   425,859  
  Other long-term liabilities -   48  
  Provisions 6,487   6,180  
  Pensions 92,646   87,164  
  Post-retirement benefits 57,162   57,346  
  Liabilities to non-unitholders 808,435   783,851  
  Current portion of Partnership units liability 8,611   2,630  
  Long-term portion of Partnership units liability 137,296   122,546  
  Total Partnership units liability 145,907   125,176  
Total liabilities 954,342   909,027  
         
Equity        
  Partnership units 336,576   318,012  
  Deficit (42,792 ) (29,416 )
  Accumulated other comprehensive income 88,849   99,805  
Total equity 382,633   388,401  
Total equity and liabilities 1,336,975   1,297,428  
         
         
         
Kruger Products L.P.  
Consolidated Statement of Comprehensive Income  
(thousands of Canadian dollars)  
                 
  13-week   13-week          
  period ended   period ended   Year ended   Year ended  
  December 31, 2016   December 31, 2015   December 31, 2016   December 31, 2015  
  $   $   $   $  
                 
Revenue 339,626   300,583   1,227,896   1,138,870  
                 
Expenses                
  Cost of sales 284,299   259,842   1,031,647   970,759  
  Selling, general and administrative expenses 26,480   23,452   92,763   87,978  
  Gain on sale of non-financial assets (2,544 ) 12   (2,939 ) (1,119 )
  Restructuring costs, net 134   989   552   2,824  
                 
Operating income 31,257   16,288   105,873   78,428  
                 
  Interest expense 10,673   10,095   44,000   58,164  
  Other expense 23,061   561   22,754   11,331  
                 
Income (loss) before income taxes (2,477 ) 5,632   39,119   8,933  
                 
Income taxes 2,017   6,157   3,629   7,439  
                 
Net income (loss) for the period (4,494 ) (525 ) 35,490   1,494  
                 
Other comprehensive income (loss)                
  Items that will not be reclassified to net income (loss):                
  Remeasurements of pensions 55,495   11,217   (8,491 ) 7,094  
  Remeasurements of post-retirement benefits 4,613   (1,965 ) 94   (2,667 )
  Items that may be subsequently reclassified to net income (loss):                
  Available-for-sale investment -   513   (290 ) 207  
  Cumulative translation adjustment 6,192   13,242   (10,666 ) 56,135  
                 
Total other comprehensive income (loss) for the period 66,300   23,007   (19,353 ) 60,769  
                 
Comprehensive income for the period 61,806   22,482   16,137   62,263  
                 
                 
                 
Kruger Products L.P.  
Consolidated Statement of Cash Flows  
(thousands of Canadian dollars)  
                 
  13-week   13-week          
  period ended   period ended   Year ended   Year ended  
  December 31, 2016   December 31, 2015   December 31, 2016   December 31, 2015  
  $   $   $   $  
Cash flows from (used in) operating activities                
Net income (loss) for the period (4,494 ) (525 ) 35,490   1,494  
Items not affecting cash                
  Depreciation 13,661   12,189   47,436   41,643  
  Amortization 270   318   1,146   881  
  Loss on sale of fixed assets 142   450   139   734  
  Change in amortized cost of Partnership units liability 22,129   (1,010 ) 23,363   4,003  
  Gain on sale of investment -   -   (324 ) -  
  Foreign exchange (gain) loss 932   1,578   (285 ) 6,906  
  Interest expense 10,673   10,095   44,000   58,164  
  Pension and post retirement benefits 2,597   2,685   10,402   14,146  
  Provisions 147   229   1,338   3,034  
  Income taxes 2,017   6,157   3,629   7,439  
  Gain on sale of non-financial assets (2,544 ) 12   (2,939 ) (1,119 )
  Total items not affecting cash 50,024   32,703   127,905   135,831  
                 
Net change in non-cash working capital 11,857   (4,382 ) 1,386   (24,540 )
Contributions to pension and post-retirement benefit plans (4,417 ) (11,553 ) (18,335 ) (23,084 )
Provisions paid (815 ) (2,580 ) (2,267 ) (3,558 )
Income tax payments (83 ) (557 ) (1,970 ) (2,107 )
                 
Net cash from operating activities 52,072   13,106   142,209   84,036  
                 
Cash flows from (used in) investing activities                
Purchases of property, plant & equipment (22,794 ) (21,552 ) (81,460 ) (54,701 )
Capitalized interest paid (222 ) -   (222 ) -  
Proceeds on sale of investment -   -   1,439   -  
Government assistance received 1,191   -   2,400   -  
Purchases of software (492 ) (722 ) (563 ) (2,682 )
Proceeds on sale of property, plant and equipment 4,860   -   5,399   736  
                 
Net cash used in investing activities (17,457 ) (22,274 ) (73,007 ) (56,647 )
                 
Cash flows from (used in) financing activities                
Proceeds from long-term debt 4,614   206,000   9,609   206,000  
Repayment of long-term debt (9,776 ) (179,976 ) (17,882 ) (184,856 )
Payment of deferred financing fees (34 ) (1,248 ) (745 ) (1,388 )
Interest paid on long-term debt (15,868 ) (22,603 ) (34,162 ) (44,978 )
Distributions and advances paid, net (5,979 ) (7,156 ) (22,862 ) (31,811 )
Proceeds from issuing Partnership units -   -   -   195  
                 
Net cash used in financing activities (27,043 ) (4,983 ) (66,042 ) (56,838 )
                 
Effect of exchange rate changes on cash and cash equivalents held in foreign currency
408
 
1,059
 
(1,111

)

3,116
 
                 
Increase (decrease) in cash and cash equivalents during the period 7,980   (13,092 ) 2,049   (26,333 )
                 
Cash and cash equivalents - Beginning of period 19,524   38,547   25,455   51,788  
                 
Cash and cash equivalents - End of period 27,504   25,455   27,504   25,455  
                 
                 
                 
Kruger Products L.P.  
Segment and Geographic Results  
(thousands of Canadian dollars)  
                 
  13-week   13-week          
  period ended   period ended   Year ended   Year ended  
  December 31, 2016   December 31, 2015   December 31, 2016   December 31, 2015  
  $   $   $   $  
                 
Segment Information                
                 
Segment Revenue                
  Consumer 277,543   240,583   986,881   897,959  
  AFH 59,549   54,799   227,062   220,320  
  Other 2,534   5,201   13,953   20,591  
                 
Total segment revenue 339,626   300,583   1,227,896   1,138,870  
                 
Segment Adjusted EBITDA                
  Consumer 41,934   30,726   146,367   122,483  
  AFH 987   621   5,217   5,407  
  Other (1 ) (1,094 ) 947   (1,505 )
                 
Total segment Adjusted EBITDA 42,920   30,253   152,531   126,385  
                 
Reconciliation to Net Income (Loss):                
                 
Depreciation and amortization 13,931   12,507   48,582   42,524  
Interest expense 10,673   10,095   44,000   58,164  
Change in amortized cost of Partnership units liability 22,129   (1,010 ) 23,363   4,003  
Loss on sale of fixed assets 142   450   139   734  
Pension revaluation - past service cost -   -   -   3,416  
Gain on sale of non-financial assets (2,544 ) 12   (2,939 ) (1,119 )
Restructuring costs 134   989   552   2,824  
Foreign exchange (gain) loss 932   1,578   (285 ) 6,906  
                 
Income (loss) before income taxes (2,477 ) 5,632   39,119   8,933  
                 
Income taxes 2,017   6,157   3,629   7,439  
                 
Net income (loss) (4,494 ) (525 ) 35,490   1,494  
                 
Geographic Revenue                
                 
Canada 209,605   184,512   746,483   711,881  
U.S. 115,767   103,384   429,627   389,154  
Mexico 14,254   12,687   51,786   37,835  
                 
Total revenue 339,626   300,583   1,227,896   1,138,870  
                 
                 
                 
KP Tissue Inc.  
Statement of Financial Position  
(thousands of Canadian dollars)  
         
  December 31, 2016   December 31, 2015  
  $   $  
Assets        
         
Current assets        
  Distributions receivable 1,636   1,613  
  Receivable from Partnership 426   -  
  Income tax recoverable -   828  
  2,062   2,441  
         
Non-current assets        
  Investment in associate 117,349   126,643  
         
Total Assets 119,411   129,084  
         
Liabilities        
         
Current liabilities        
  Dividend payable 1,636   1,613  
  Payable to Partnership -   108  
  Current portion of advances from Partnership 914   432  
  Income tax payable 884   -  
  3,434   2,153  
Non-current liabilities        
  Advances from Partnership -   709  
  Deferred income taxes 893   1,007  
         
Total liabilities 4,327   3,869  
         
Equity        
         
  Common shares 13,176   11,577  
  Contributed surplus 144,819   144,819  
  Deficit (58,729 ) (49,291 )
  Accumulated other comprehensive income 15,818   18,110  
         
Total equity 115,084   125,215  
         
Total liabilities and equity 119,411   129,084  
         
         
         
KP Tissue Inc.  
Statement of Comprehensive Income (Loss)  
(thousands of Canadian dollars, except share and per share amounts)  
                 
  13-week   13-week          
  period ended   period ended   Year ended   Year ended  
  December 31, 2016   December 31, 2015   December 31, 2016   December 31, 2015  
  $   $   $   $  
                 
Equity loss (2,225 ) (1,516 ) (124 ) (5,480 )
                 
Dilution gain (loss) 49   (59 ) 191   70  
                 
Impairment in investment in associate -   (28,000 ) -   (28,000 )
                 
Income (loss) before income taxes (2,176 ) (29,575 ) 67   (33,410 )
                 
Income taxes (1,768 ) (1,796 ) 1,789   (2,066 )
                 
Net loss for the period (408 ) (27,779 ) (1,722 ) (31,344 )
                 
Other comprehensive income (loss) net of tax expense (recovery)                
  Items that will not be reclassified to net loss:                
  Remeasurements of pensions 7,839   1,603   (1,195 ) 1,013  
  Remeasurements of post-retirement benefits 456   (196 ) 9   (267 )
  Items that may be subsequently reclassified to net loss:                
  Available-for-sale investment -   72   (41 ) 29  
  Cumulative translation adjustment 1,244   2,376   (2,251 ) 10,223  
                 
Total other comprehensive income (loss) for the period 9,539   3,855   (3,478 ) 10,998  
                 
Comprehensive income (loss) for the period 9,131   (23,924 ) (5,200 ) (20,346 )
                 
Basic loss per share (0.04 ) (3.12 ) (0.19 ) (3.52 )
                 
Weighted average number of shares outstanding 9,084,494   8,952,820   9,037,833   8,910,948  
                 
                 
                 
KP Tissue Inc.  
Statement of Cash Flows  
(thousands of Canadian dollars)  
                 
  13-week   13-week          
  period ended   period ended   Year ended   Year ended  
  December 31, 2016   December 31, 2015   December 31, 2016   December 31, 2015  
  $   $   $   $  
Cash flows from (used in) operating activities                
Net loss for the period (408 ) (27,779 ) (1,722 ) (31,344 )
Items not affecting cash                
  Equity loss 2,225   1,516   124   5,480  
  Dilution gain (loss) (49 ) 59   (191 ) (70 )
  Impairment in investment in associate -   28,000   -   28,000  
  Income taxes (1,768 ) (1,796 ) 1,789   (2,066 )
  Total items not affecting cash 408   27,779   1,722   31,344  
                 
Tax payments -   (307 ) (205 ) (1,712 )
Tax Distribution received -   -   -   571  
Advances received -   307   205   1,141  
                 
Net cash from (used in) operating activities -   -   -   -  
                 
Cash flows from (used in) investing activites                
Investment in associate -   -   -   (195 )
Partnership unit distributions received 1,180   1,205   4,908   5,217  
                 
Net cash from investing activities 1,180   1,205   4,908   5,022  
                 
Cash flows from (used in) financing activities                
Issuance of common shares -   -   -   195  
Dividends paid (1,180 ) (1,205 ) (4,908 ) (5,217 )
                 
Net cash used in financing activities (1,180 ) (1,205 ) (4,908 ) (5,022 )
                 
Increase (decrease) in cash and cash equivalents during the period -   -   -   -  
                 
Cash and cash equivalents - Beginning of period -   -   -   -  
                 
Cash and cash equivalents - End of period -   -   -   -  
   
   

INFORMATION:
Francois Paroyan
General Counsel and Corporate Secretary
KP Tissue Inc.
905.812.6936
francois.paroyan@krugerproducts.ca

INVESTORS:
Mike Baldesarra
Director of Investor Relations
KP Tissue Inc.
905.812.6962
IR@KPTissueinc.com

Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. View delay times for all exchanges. Market Data powered by QuoteMedia. See the QuoteMedia Terms of Use.